Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is 16.23% higher on its value in year-to-date trading and has touched a low of $99.98 and a high of $150.39 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NBIX stock was last observed hovering at around $141.57 in the last trading session, with the day’s gains setting it 11.58%.
Currently trading at $153.15, the stock is 5.96% and 9.74% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.03 million and changing 8.18% at the moment leaves the stock 16.13% off its SMA200. NBIX registered 48.06% gain for a year compared to 6-month loss of 9.57%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 11.39% gain in the last 1 month and extending the period to 3 months gives it a 7.08%, and is 4.83% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.92% over the week and 2.72% over the month.
Neurocrine Biosciences, Inc. (NBIX) has around 1400 employees, a market worth around $15.41B and $1.98B in sales. Current P/E ratio is 42.10 and Fwd P/E is 22.37. Profit margin for the company is 18.65%. Distance from 52-week low is 53.18% and 1.84% from its 52-week high. The company has generated returns on investments over the last 12 months (14.01%).
The EPS is expected to grow by 86.29% this year
The shares outstanding are 98.70M, and float is at 98.41M with Short Float at 2.67%.
Neurocrine Biosciences, Inc. (NBIX) Insider Activity
The most recent transaction is an insider sale by Lippoldt Darin, the company’s Chief Legal Officer. SEC filings show that Lippoldt Darin sold 7,004 shares of the company’s common stock on Jul 16 ’24 at a price of $150.00 per share for a total of $1.05 million. Following the sale, the insider now owns 39740.0 shares.
Neurocrine Biosciences, Inc. disclosed in a document filed with the SEC on Jul 16 ’24 that Delaet Ingrid (Chief Regulatory Officer) sold a total of 2,857 shares of the company’s common stock. The trade occurred on Jul 16 ’24 and was made at $150.03 per share for $0.43 million. Following the transaction, the insider now directly holds 6607.0 shares of the NBIX stock.
Still, SEC filings show that on Jul 16 ’24, LYONS GARY A (Director) disposed off 930 shares at an average price of $150.03 for $0.14 million. The insider now directly holds 119,047 shares of Neurocrine Biosciences, Inc. (NBIX).
